The excessive Dialysis Product Pricing case targets Adcock Ingram, with a possible 10% turnover penalty and wider renal care cost impacts.
Excessive Dialysis Product Pricing: Adcock Ingram Referred
Original Article by Tamar Kahn | Business Day | 4 June 2026
The excessive Dialysis Product Pricing case targets Adcock Ingram, with a possible 10% turnover penalty and wider renal care cost impacts.
More Posts
Mpox Cases in SA Rise as Local Transmission Accelerates
Mpox cases in South Africa are rising, mainly in the Western Cape. What the surge means for the healthcare industry.
Read more...
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...
Momentum Group Posts Record Earnings
Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.
Read more...